CU23608A3 - Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada - Google Patents

Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada

Info

Publication number
CU23608A3
CU23608A3 CU20050206A CU20050206A CU23608A3 CU 23608 A3 CU23608 A3 CU 23608A3 CU 20050206 A CU20050206 A CU 20050206A CU 20050206 A CU20050206 A CU 20050206A CU 23608 A3 CU23608 A3 CU 23608A3
Authority
CU
Cuba
Prior art keywords
deficient
nucleic acid
tuberculosis
acid molecules
ureasa
Prior art date
Application number
CU20050206A
Other languages
English (en)
Inventor
Juergen Hess
Baerbel Raupach
Stefan H E Kaufmann
Leander Grode
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of CU23608A3 publication Critical patent/CU23608A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas vacunas recombinantes deficientes en ureasa que proporcionan inmunidad protectora contra la tuberculosis. Adicionalmente, la presente invención se refiere a nuevas moléculas de ácido nucleico recombinante, vectores que contiene dichas moléculas de ácido nucleico, células transformadas con dichas moléculas de ácido nucleico y polipéptidos codificados por dichas moléculas de ácido nucleico.
CU20050206A 2003-04-23 2005-10-26 Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada CU23608A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
CU23608A3 true CU23608A3 (es) 2010-12-08

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050206A CU23608A3 (es) 2003-04-23 2005-10-26 Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada

Country Status (23)

Country Link
US (2) US7988980B2 (es)
EP (1) EP1618128B1 (es)
JP (1) JP4662925B2 (es)
KR (1) KR101101263B1 (es)
CN (1) CN1798762B (es)
AT (1) ATE473238T1 (es)
AU (1) AU2004232485B2 (es)
BR (1) BRPI0409789B8 (es)
CA (1) CA2523084C (es)
CU (1) CU23608A3 (es)
CY (1) CY1110793T1 (es)
DE (1) DE602004028000D1 (es)
DK (1) DK1618128T3 (es)
ES (1) ES2344698T3 (es)
HR (1) HRP20100395T1 (es)
MX (1) MXPA05011360A (es)
PL (1) PL1618128T3 (es)
PT (1) PT1618128E (es)
RU (1) RU2342400C2 (es)
SI (1) SI1618128T1 (es)
UA (1) UA91180C2 (es)
WO (1) WO2004094469A1 (es)
ZA (1) ZA200508276B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4662925B2 (ja) * 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
WO2007058663A2 (en) 2004-12-01 2007-05-24 Aeras Global Tb Vaccine Foundation Recombinant bcg strains with enhanced ability to escape the endosome
US8741313B2 (en) * 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
RS60146B1 (sr) * 2010-09-20 2020-05-29 Vakzine Projekt Man Gmbh Rekombinantna mycobacterium kao vakcina za upotrebu kod ljudi
CN103270048B (zh) 2010-11-10 2016-11-23 热体实验室有限公司 新型佐剂
HRP20160558T1 (hr) * 2010-12-21 2016-06-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Određivanje efikasnosti živog rekombinantnog anti-mikobakterijskog cijepljenja
SI2654783T1 (sl) 2010-12-21 2017-02-28 Max-Planck-Gesellschaft zur Fourderung der Wissenschaften e.V. Rekombinantni mycobacterium kot cepivo
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
WO2017046409A1 (en) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
RU2760580C2 (ru) * 2017-04-07 2021-11-29 Ченду Йоньгань Фармасьютикал Ко., Лтд. РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR
US10387139B2 (en) * 2017-07-25 2019-08-20 Aurora Labs Ltd. Opportunistic software updates during select operational modes
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
KR20230084177A (ko) * 2020-10-09 2023-06-12 제리아 신야쿠 고교 가부시키 가이샤 결핵균 추출물의 신규 용도
KR20240082332A (ko) 2021-07-22 2024-06-10 세럼 라이프 사이언스 유럽 게엠베하 방광암종의 2차 치료를 위한 면역치료제로서의 재조합 마이코박테리움
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533818B1 (ko) * 1996-12-18 2005-12-07 스탠포드 룩 리미티드 면역계의 ｔｈ2 활성의 하향 조절을 위한 마이코박테리움 박케
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
JP4662925B2 (ja) * 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン

Also Published As

Publication number Publication date
BRPI0409789B8 (pt) 2021-05-25
BRPI0409789A (pt) 2006-05-30
CY1110793T1 (el) 2015-06-10
RU2342400C2 (ru) 2008-12-27
UA91180C2 (ru) 2010-07-12
KR101101263B1 (ko) 2012-01-04
HK1091217A1 (zh) 2007-01-12
WO2004094469A1 (en) 2004-11-04
MXPA05011360A (es) 2005-11-28
JP2007524367A (ja) 2007-08-30
RU2005136354A (ru) 2006-03-20
CN1798762A (zh) 2006-07-05
KR20050114281A (ko) 2005-12-05
ATE473238T1 (de) 2010-07-15
CA2523084A1 (en) 2004-11-04
US8545854B2 (en) 2013-10-01
ES2344698T3 (es) 2010-09-03
ZA200508276B (en) 2006-06-28
HRP20100395T1 (hr) 2010-09-30
PT1618128E (pt) 2010-10-13
US20120027794A1 (en) 2012-02-02
JP4662925B2 (ja) 2011-03-30
US7988980B2 (en) 2011-08-02
AU2004232485B2 (en) 2009-11-26
EP1618128B1 (en) 2010-07-07
DK1618128T3 (da) 2010-10-18
BRPI0409789B1 (pt) 2018-10-16
AU2004232485A1 (en) 2004-11-04
DE602004028000D1 (de) 2010-08-19
PL1618128T3 (pl) 2010-12-31
CN1798762B (zh) 2010-04-28
SI1618128T1 (sl) 2010-11-30
EP1618128A1 (en) 2006-01-25
CA2523084C (en) 2012-09-04
US20070134267A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
CU23608A3 (es) Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada
CY1106350T1 (el) Εμβολιο φυματιωσης
CR9443A (es) Vacuna de toxoide de c. perfringens alfa
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
MX2010001284A (es) Vacunas contra la influenza con multiepitope multimerico.
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
MX2010005589A (es) Composicion para el cuidado personal.
CO6331298A2 (es) Vacunas contra coccidiosis
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
WO2007024947A3 (en) Canine influenza vaccines
BR0011469A (pt) Gm-csf equina
MX2020011298A (es) Composiciones de antígeno micobacteriano y métodos de uso.
AR052947A1 (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican para los mismos
BR0308180A (pt) protéinas de superfìcie de leptospira
BR0013574A (pt) Antìgeno vacina de moraxella
MX2010008170A (es) Vacunas para influenza canina.
DE60324285D1 (de) Immunmodulatorische konstrukte und deren verwendungen
WO2004087888A3 (en) Neurotransmitter signaling can regulate life span in c. elegans
ITVR20040049A1 (it) Elemento di protezione per cassoni di veicoli indstriali
AR073595A1 (es) Vacunas que contienen variantes geneticas de parvovirus canino
UA103306C2 (en) Normal;heading 1;heading 2;heading 3;HUMAN C-FMS ANTIGEN BINDING PROTEINS
TW200736272A (en) Isolated chitinase, DNA, recombinant vector, recombinant chitinase and expression system thereof
BRMU8501075U (pt) protetor para catalisador automotivo

Legal Events

Date Code Title Description
FG Grant of patent